{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"117-865-104-791-253","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"117-865-104-791-253"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10771,"type":"PATENT","title":"University of Southern California - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8387,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8241,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Trp-Arg-Glu-Pro-Ser-Phe-Met-Ala-Leu-Ser (SEQ ID NO:3)."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The retroviral vector particle of Claim 2 wherein said retroviral vector particle include a first retroviral envelope and a second retroviral envelope, wherein each of said first retroviral envelope and said second retroviral envelope includes (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion; and wherein said first retroviral envelope is free of non-retroviral peptides, and said second retroviral envelope is a modified retroviral envelope wherein said targeting polypeptide is inserted between two contiguous amino acid residues of said second retroviral envelope."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The retroviral vector particle of Claim 7 wherein said targeting polypeptide is inserted between two consecutively numbered amino acid residues of the receptor binding region of said second retroviral envelope."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The retroviral vector particle of Claim 8 wherein prior to modification the receptor binding region of said second retroviral envelope has the sequence (SBQ ID NO:1), and said targeting polypeptide is inserted between amino acid residues 18 and 19 of (SEQ ID NO:1)."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The retroviral vector particle of Claim 7 wherein said extracellular matrix component is collagen."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The retroviral vector particle of Claim 10 wherein said binding region which binds to collagen has the following structure:
Trp-Arg-Glu-Pro-Ser-Phe-Met-Ala-Leu-Ser (SBQ ID NO:3)"],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A modified polynucleotide encoding a modified viral surface protein for targeting a vector to an extracellular matrix component, wherein the modified polynucleotide includes a polynucleotide encoding a targeting polypeptide, said targeting polypeptide including a binding region which binds to an extracellular matrix component."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The modified polynucleotide of Claim 12 wherein said modified polynucleotide encodes a modified retroviral envelope polypeptide."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The modified polynucleotide of Claim 13 wherein said retroviral envelope polypeptide includes a receptor binding region, wherein, in the modified polynucleotide, the polynucleotide encoding the receptor binding region is modified to include a polynucleotide encoding a targeting polypeptide including a binding region which binds to an extracellular matrix component."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The modified polynucleotide of Claim 14 wherein, prior to modification, the polynucleotide encoding the receptor binding region encodes a receptor binding region having the sequence (SBQ ID NO:1) and in the modified polynucleotide, said polynucleotide encoding said targeting polypeptide is inserted between the codon encoding amino acid residue 18 and the codon encoding amino acid residue 19."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A producer cell for producing a retroviral vector particle having a modified envelope polypeptide, said producer cell including the modified polynucleotide of Claim 8."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The retroviral vector particle of Claim 2 and further including at least one polynucleotide encoding a therapeutic agent."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["A method of expressing a therapeutic agent in an animal, comprising:
administering to an animal the retroviral vector particles of Claim 17."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A modified retroviral envelope polypeptide wherein, prior to modification, the envelope includes a polypeptide having the sequence (SEQ ID NO:1), and wherein, in the modified envelope, a targeting polypeptide including a binding region which binds to an extracellular matrix component is inserted between amino acid residue 18 and amino acid residue 19 of (SEQ ID NO:1)."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of Claim 19 wherein said binding region binds to collagen."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of Claim 20 wherein said binding region which binds to collagen has the following structure:
Trp-Arg-Glu-Pro-Ser-Phe-Met-Ala-Leu-Ser (SEQ ID NO:3)."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A retroviral plasmid vector including the modified polynucleotide of Claim 13."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["A method of generating retroviral vector particles, comprising:
(a) transfecting a cell line selected from the group consisting of (i) a pre-packaging cell line including polynucleotides encoding the gag and pol retroviral proteins; and (ii) a packaging cell line including polynucleotides encoding the gag, pol, and env retroviral proteins with the retroviral plasmid vector of Claim 22 to form a producer cell line; and
(b) culturing said producer cell line to generate retroviral vector particles."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["A proteoliposome including a wall, wherein said wall of said proteoliposome includes a targeting polypeptide including a binding region which binds to an extracellular matrix component."],"number":24,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}